463 related articles for article (PubMed ID: 33172895)
21. MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer.
Nickols NG; Nazarian R; Zhao SG; Tan V; Uzunangelov V; Xia Z; Baertsch R; Neeman E; Gao AC; Thomas GV; Howard L; De Hoedt AM; Stuart J; Goldstein T; Chi K; Gleave ME; Graff JN; Beer TM; Drake JM; Evans CP; Aggarwal R; Foye A; Feng FY; Small EJ; Aronson WJ; Freedland SJ; Witte ON; Huang J; Alumkal JJ; Reiter RE; Rettig MB
Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):531-538. PubMed ID: 30804427
[TBL] [Abstract][Full Text] [Related]
22. BRAF
Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
[TBL] [Abstract][Full Text] [Related]
23. Zoledronic acid enhances the efficacy of the MEK inhibitor trametinib in KRAS mutant cancers.
Dai X; Xia H; Zhou S; Tang Q; Bi F
Cancer Lett; 2019 Feb; 442():202-212. PubMed ID: 30429107
[TBL] [Abstract][Full Text] [Related]
24. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.
Gilmartin AG; Bleam MR; Groy A; Moss KG; Minthorn EA; Kulkarni SG; Rominger CM; Erskine S; Fisher KE; Yang J; Zappacosta F; Annan R; Sutton D; Laquerre SG
Clin Cancer Res; 2011 Mar; 17(5):989-1000. PubMed ID: 21245089
[TBL] [Abstract][Full Text] [Related]
25. YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling.
Coggins GE; Farrel A; Rathi KS; Hayes CM; Scolaro L; Rokita JL; Maris JM
Cancer Res; 2019 Dec; 79(24):6204-6214. PubMed ID: 31672841
[TBL] [Abstract][Full Text] [Related]
26. Monosomy 3 Is Linked to Resistance to MEK Inhibitors in Uveal Melanoma.
Mergener S; Siveke JT; Peña-Llopis S
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201614
[TBL] [Abstract][Full Text] [Related]
27. Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity.
Hartman ML; Sztiller-Sikorska M; Gajos-Michniewicz A; Czyz M
Cells; 2020 Jan; 9(1):. PubMed ID: 31936151
[TBL] [Abstract][Full Text] [Related]
28.
Bridges AE; Ramachandran S; Pathania R; Parwal U; Lester A; Rajpurohit P; Morera DS; Patel N; Singh N; Korkaya H; Manicassamy S; Prasad PD; Lokeshwar VB; Lokeshwar BL; Ganapathy V; Thangaraju M
Cancer Res; 2020 Sep; 80(18):3855-3866. PubMed ID: 32665355
[TBL] [Abstract][Full Text] [Related]
29. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC
Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228
[TBL] [Abstract][Full Text] [Related]
30. Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer.
Matissek KJ; Onozato ML; Sun S; Zheng Z; Schultz A; Lee J; Patel K; Jerevall PL; Saladi SV; Macleay A; Tavallai M; Badovinac-Crnjevic T; Barrios C; Beşe N; Chan A; Chavarri-Guerra Y; Debiasi M; Demirdögen E; Egeli Ü; Gökgöz S; Gomez H; Liedke P; Tasdelen I; Tolunay S; Werutsky G; St Louis J; Horick N; Finkelstein DM; Le LP; Bardia A; Goss PE; Sgroi DC; Iafrate AJ; Ellisen LW
Cancer Discov; 2018 Mar; 8(3):336-353. PubMed ID: 29242214
[TBL] [Abstract][Full Text] [Related]
31. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
[TBL] [Abstract][Full Text] [Related]
32. Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways.
Iwanaga R; Wang CA; Micalizzi DS; Harrell JC; Jedlicka P; Sartorius CA; Kabos P; Farabaugh SM; Bradford AP; Ford HL
Breast Cancer Res; 2012 Jul; 14(4):R100. PubMed ID: 22765220
[TBL] [Abstract][Full Text] [Related]
33. Global view of the RAF-MEK-ERK module and its immediate downstream effectors.
Santini CC; Longden J; Schoof EM; Simpson CD; Jeschke GR; Creixell P; Kim J; Wu X; Turk BE; Rosen N; Poulikakos PI; Linding R
Sci Rep; 2019 Jul; 9(1):10865. PubMed ID: 31350469
[TBL] [Abstract][Full Text] [Related]
34. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance.
Balko JM; Cook RS; Vaught DB; Kuba MG; Miller TW; Bhola NE; Sanders ME; Granja-Ingram NM; Smith JJ; Meszoely IM; Salter J; Dowsett M; Stemke-Hale K; González-Angulo AM; Mills GB; Pinto JA; Gómez HL; Arteaga CL
Nat Med; 2012 Jul; 18(7):1052-9. PubMed ID: 22683778
[TBL] [Abstract][Full Text] [Related]
35. Physapubescin B enhances the sensitivity of gastric cancer cells to trametinib by inhibiting the STAT3 signaling pathway.
Dai C; Shen L; Jin W; Lv B; Liu P; Wang X; Yin Y; Fu Y; Liang L; Ma Z; Zhang X; Wang Y; Xu D; Chen Z
Toxicol Appl Pharmacol; 2020 Dec; 408():115273. PubMed ID: 33035574
[TBL] [Abstract][Full Text] [Related]
36. Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis.
Bergamaschi A; Christensen BL; Katzenellenbogen BS
Breast Cancer Res; 2011 Jun; 13(3):R70. PubMed ID: 21707964
[TBL] [Abstract][Full Text] [Related]
37. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.
Johnson GL; Stuhlmiller TJ; Angus SP; Zawistowski JS; Graves LM
Clin Cancer Res; 2014 May; 20(10):2516-22. PubMed ID: 24664307
[TBL] [Abstract][Full Text] [Related]
38. Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA
Cheng F; Zhao J; Hanker AB; Brewer MR; Arteaga CL; Zhao Z
Breast Cancer Res Treat; 2016 Dec; 160(3):457-474. PubMed ID: 27771839
[TBL] [Abstract][Full Text] [Related]
39. EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition.
Mizukami T; Togashi Y; Sogabe S; Banno E; Terashima M; De Velasco MA; Sakai K; Fujita Y; Tomida S; Nakajima TE; Boku N; Nishio K
Int J Oncol; 2015 Aug; 47(2):499-505. PubMed ID: 26081723
[TBL] [Abstract][Full Text] [Related]
40. Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer.
Lindberg JM; Newhook TE; Adair SJ; Walters DM; Kim AJ; Stelow EB; Parsons JT; Bauer TW
Neoplasia; 2014 Jul; 16(7):562-71. PubMed ID: 25117978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
